It’s time to get back into marijuana stocks, says Canaccord Genuity

After a three-month bout of profit taking in the cannabis sector, the bottom may have finally been reached for some stocks, says analyst Javed Mirza of Canaccord Geniuty, who recommends adding exposure in the space.

Canada’s pot stocks continued their downward slide this past week, with industry leaders like Canopy Growth Corp. (TSX:WEED) and Aurora Cannabis (TSX:ACB) just about hitting new lows for 2018. The Horizons Marijuana Life Sciences ETF is down 40 per cent from its early January peak, while the Canadian Marijuana Index closed down another 2.9 per cent for the week.

But a short-term counter-trend bounce appears to be taking hold, says Mirza in a quantitative/technical overview on Wednesday. The analyst suggests adding exposure for a short-term trade idea that could turn long-term if equity markets resume their uptrends.

“From a fundamental perspective, we believe there has been little news flow to explain the magnitude of the downward move in the cannabis sector as of late and that investors could be taking profits in riskier sectors,” says the analyst.

“Looking ahead, we believe that sector multiple expansion could resume in the near term as we await positive catalysts such as the announcement of rec purchase commitments from Ontario, additional progress towards federal legalization, and the potential for further consolidation, M&A and the entrance of strategic partners in the space,” he says.

“It’s not until the rubber hits the road in the second half of the year with the roll out of legal adult-use marijuana in Canada that we envision potential negative operational catalysts,” Mirza says.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

3 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

4 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

4 days ago